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ABSTRACT
The DNA repair protein O6-alkylguanine-DNA alkyltransferase (AGT)
protects cells from alkylation damage. O6-Benzylguanine (BG) is a potent
inactivator of human AGT (ED50 of 0.1 mM) that is currently undergoing
clinical trials to enhance chemotherapy by alkylating agents. In a screen
of AGT mutants randomly mutated at position glycine-160, we found that
the double mutant Y158H/G160A protected Escherichea coli from killing
by N-methyl-N*-nitro-N-nitrosoguanidine (MNNG) even in the presence
of BG and that the AGT activity of this mutant was strongly resistant to
BG (ED50 of 180 mM). Because the single mutant G160A was not resistant
to BG, this suggested that the presence of the charged histidine residue at
position 158 was responsible. This hypothesis was confirmed by the con-
struction of the single mutation Y158H. The Y158H-mutant AGT was
slightly less active than wild-type AGT for the repair of methylated DNA
in vitro, but it protected E. coli from killing by MNNG even in the presence
of BG and had an ED50 for the inactivation by BG of 620 mM. In contrast,
mutant Y158F had an ED50 of 0.2 mM. Previous studies (M. Xu-Welliver
et al., Cancer Res., 58: 1936–1945, 1998) have shown that mutant P140K
is highly resistant to BG (ED50 of >1200 mM). Models of human AGT
suggest that the side chain of the lysine inserted into this mutant is close
to tyrosine-158 and that the positively charged lysine side-chain may
interfere with BG binding. The double mutants P140K/Y158H and
P140K/Y158F resembled P140K and Y158H in being highly resistant
to BG, but the use of a sensitive assay for reaction of BG with AGT
indicated that their abilities to react were in the order P140K/
Y158H < P140K < P140K/Y158F. These results confirm that the presence
of a positively charged residue close to the active site of human AGT
renders it highly resistant to BG without substantially affecting activity
toward methylated DNA substrates. Such mutants may limit the value of
BG therapy if they arise in malignant cells during chemotherapy, but the
mutant sequences may be useful for gene therapy approaches in which
BG-resistant human AGTs are used to prevent hematopoietic toxicity. At
least 28 AGT sequences (from 25 species) have now been described. In 25
of these, the position equivalent to 158 in the human AGT is also a
tyrosine, and in the other 3, it is a phenylalanine. The importance of an
aromatic ring side chain at this position is emphasized by previous studies
(S. Edara et al., Carcinogenesis, 16: 1637–1642, 1995), which show that the
replacement by alanine renders human AGT inactive. Our results show
that histidine can also substitute for tyrosine at this position.
INTRODUCTION
An important site of damage to DNA produced by reaction with
alkylating agents is the O6 position of guanine (1–4). This adduct is
removed by the action of the DNA repair protein AGT.4 AGT acts to
transfer the alkyl group to a cysteine acceptor site (located at residue
145 in human AGT) and to restore the DNA in a single step. The
presence of AGT is known to protect cells from alkylating agent-
mediated toxicity including mutagenesis, cell killing, and carcinogen-
esis. However, the presence of AGT in tumors provides resistance to
therapeutic alkylating agents (5–7). Human AGT is strongly inhibited
by BG (8). BG acts as a substrate for AGT. It is bound at the active
site, and AGT-mediated transfer of the benzyl group to the cysteine
acceptor site causes its inactivation (9). The combination of BG and
BCNU is currently undergoing clinical trials for cancer chemotherapy
(6, 7, 10).
AGT appears to be a very widely distributed protein, and sequences
are now known from at least 25 different species. Some of the
microbial AGTs have been found to be very resistant to inactivation
by BG (9). Several human AGT mutants with a reduced ability to
react with BG have been obtained either by site-directed mutagenesis
(11–14) or by screening cDNA libraries containing random insertions
in the AGT sequences for the ability to protect E. coli from killing by
MNNG in the presence of BG (14–16).
Such resistant mutants are of interest for several reasons: (a) they
suggest that resistance to BG therapy may arise relatively readily, and
it will be necessary to obtain additional AGT inhibitors able to
inactivate these resistant mutants; (b) the comparison of BG-sensitive
and BG-resistant AGT mutants provides more information about the
interaction of the protein and the drug that should prove valuable in
designing improved inhibitors with greater potency and specificity;
and (c) the dose-limiting toxicity of therapy with BG plus alkylating
agents is myelosuppression, which is due to the very low level of AGT
in bone marrow progenitor cells (17, 18). The use of a BG-resistant
AGT-mutant protein for gene therapy approaches in which an AGT is
expressed from a suitable vector in hematopoietic cells may overcome
this toxicity and improve the chemotherapeutic index of the treatment
because the tumor would remain sensitive whereas the bone marrow
would be resistant (19–22).
We (12–14) and others (15, 16) have, therefore, been attempting to
produce a panel of BG-resistant mutants and to identify the major
factors involved in permitting AGT to continue to work on DNA
adducts but to be inactive on BG. A screening method to obtain such
mutants was set up by using the ability of expressed human AGT to
protect a BG-permeable E. coli strain lacking endogenous alkyltrans-
ferase (TRG8) from killing by MNNG (14). This protection was
abolished by BG. We have shown that this screen can be used to
identify BG-resistant mutants in human AGT containing a random
sequence inserted in place of the codons corresponding to amino acids
138–140 (14). This screen indicated that the conversion of proline-
140 to lysine (mutant P140K) produced by far the greatest resistance
of any point mutation, increasing the ED50 value for inactivation by
more than 12,000-fold.
Received 9/24/98; accepted 2/2/99.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked advertisement in accordance with
18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported in part by National Cancer Institute Grants CA-71976,
CA-57725, and CA-18137. J. Leitao was the recipient of fellowships for mobility granted
by Foundation Calouste Gulbenkian and Luso-American Development Foundation.
2 Present address: Unidade de Ciencias e Tecnologias Agrarias, Universidade do
Algarve, Campus de Gambias, 8000 Faro, Portugal.
3 To whom requests for reprint should be addressed at Department of Cellular and
Molecular Physiology, Milton S. Hershey Medical Center, Pennsylvania State University
College of Medicine, 500 University Drive, Hershey, PA 17033. Phone: (717) 531-8152;
Fax: (717) 531-5157; E-mail: aep1@psu.edu.
4 The abbreviations used are: AGT, O6-alkylguanine-DNA alkyltransferase; BG, O6-
benzylguanine; ED50, concentration of BG needed to reduce the alkyltransferase activity
by 50% in a 30 min incubation at 37°C; MNNG, N-methyl-N9-nitro-N-nitrosoguanidine;
BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea; LB, Luria-Bertani medium.
1514
on April 29, 2016. © 1999 American Association for Cancer Research.cancerres.aacrjournals.org Downloaded from 
Another position at which human AGT can be altered to provide
resistance to BG is at glycine-160. This was discovered by the
comparison of the properties of a naturally occurring variant G160R
that was found in a minority of Japanese subjects (23) with wild-type
AGT (13). The G160R AGT was slightly more resistant to BG
(20-fold increase in ED50), whereas the mutants G160A and G160W,
which were made as controls, were found to be more sensitive than
wild type (13). The finding that G160W was sensitive to BG was later
confirmed by Rafferty et al. (24).
In the course of studies of the possible-BG resistance of an AGT-
mutant population in which the codon at position 160 was replaced by
NNS to produce a complete library covering replacements with all
amino acids, we have now found a highly BG-resistant mutant.
However, sequencing of this mutant revealed that it contained the
double change Y158H/G160A. The G160A mutation was unlikely to
explain the properties of this mutant because previous work had
shown that G160A mutant AGT is not resistant but is slightly more
sensitive than wild-type AGT (13). Also, position 158 in AGT se-
quences is highly conserved with 25 of 28 known AGT sequences
having tyrosine and the other three having the closely related phen-
ylalanine.
We have, therefore, constructed the Y158H-mutant AGT by site-
directed mutagenesis and carried out a detailed study of this and
related AGT mutants. These studies show that the Y158H AGT is
active in repairing DNA and is highly resistant to BG. Molecular
modeling studies suggest that the charged residues on the side chains
of either the P140K or the Y158H mutants may be present in the
same vicinity at the AGT active site. The presence of a charged
hydrophilic residue in this position may prevent the binding of the
hydrophobic BG.
MATERIALS AND METHODS
Materials. All oligodeoxynucleotides were purchased from Life Technol-
ogies, Inc. (Gaithersburg, MD). E. coli strain TRG8 was derived from strain
GWR109 (25) that was kindly provided by Dr. L Samson (Department of
Molecular and Cellular Toxicology, Harvard School of Public Health, Boston,
MA). pQE30 plasmid and the DNA isolation kits were obtained from Qiagen
(Chatsworth, CA). Restriction enzymes and Pfu polymerase were purchased
from New England Biolabs (Beverly, MA) and Stratagene (La Jolla, CA).
T4-ligase and the Talon Metal Affinity Resin were purchased from Clonetech
(Palo Alto, CA). Ampicillin, kanamycin, isopropyl b-D-thiogalactopyranoside,
hemocyanin, and most of the other biochemical reagents were purchased from
Sigma Chemical Co. (St. Louis, MO). BG was synthesized (8) and generously
provided by Dr. R. C. Moschel (ABL-Basic Research Program, National
Cancer Institute-Frederick Cancer Research and Development Center, Fred-
erick, MD). [8-3H]BG (0.34 mCi/mmol) was prepared by catalytic tritium
exchange of BG with tritiated water by Amersham Corporation (26).
Plasmids for Expression of AGT. AGT was expressed in the pUC-18
vector for selection and studies in E. coli extracts. Expression from the pQE or
pIN vectors was used for purification of the recombinant protein. Plasmids
pUC-AGT (14), pQE-AGT (13), pQE-P140K (14), pIN-Y158F, and pIN-
Y158A (27) have been described previously.
The pUC-Y158H mutant was made by PCR by using primer 1 (59–
CCGTTTTCCAGCAAGAGTCG-39) matching nt 310 to nt 432 in the pQE-
AGT plasmid and primer 2 (59–CCTTCACGGCTAGCCCTCCGGAGTGGT-
TGCCCACGGCTCC-39) for the mutation of the codon for tyrosine-158 to
histidine (mismatch is underlined and NheI site is shown in italics). The PCR
reaction was done using Pfu polymerase (Stratagene) with pQE-AGT plasmid
as template under the following conditions: (a) initial denaturation for 2 min at
92°C; (b) 25 cycles of denaturation (30 s at 92°C); (c) annealing (30 s at 52°C);
and (d) extension (30 s at 72°C) followed by a final extension at 72°C for 5
min. The PCR product (236 bp) was purified, digested with MluI and NheI and
ligated into the pUC-inAGT2 plasmid (described below in the next section of
“Materials and Methods”) digested with the same enzymes to form pUC-
Y158H. Plasmid pQE-Y158H was made by ligation of the 243-bp DNA
containing the sequence for the Y158H mutation (obtained by digestion of
pUC-Y158H with MluI and AgeI) with pQE-AGT digested with the same
enzymes.
The P140K/Y158H mutant AGT was generated by using pQE-P140K and
pQE-Y158H. The 1.2-kb fragment between the DraIII (at 436) and the XbaI (at
1600) restriction sites from pQE-Y158H was ligated with the 2.8-kb fragment
from pQE-P140K digested with the same enzymes to form pQE-P140K/
Y158H.
The P140K/Y158F mutant was generated by using the pQE-P140K and
pIN-Y158F DNA constructs. The 390-bp fragment from pIN-Y158F generated
by DraIII digestion (which cuts the pIN-AGT plasmid at two sites at 436 and
826 because of a site in the vector sequence) was isolated. This fragment was
further digested with the AgeI restriction enzyme (at 521), dephosphorylated,
and ligated with the large fragment from pQE-P140K digested with DraIII (at
436) and AgeI (at 521) to form pQE-P140K/Y158F.
The entire AGT coding region of all of the plasmids used for AGT
expression and activity measurements were sequenced to ensure no secondary
mutations were formed.
Construction and Screening of AGT Library with a Random Sequence
Corresponding to AGT Codon 160. A 1040-bp irrelevant inactivating se-
quence was inserted into the AGT cDNA in pGEMAGT2 (14) between the
DraIII (at 436) and the NheI (at 483) sites to prevent contamination of the
library with wild-type AGT. The DNA insert was created by PCR using Pfu
polymerase and pCM9 (28) as template with sense primer 59-GGAAGCTG-
CACAGAGTGTCGAAGGGACCGAGAAGC-39 (mismatches underlined) to
create the DraIII site (shown in italics) and the antisense primer 59-
CGACTCTAGCTAGCATCCACCACC-39 (mismatches underlined) to create
the NheI site (shown in italics). The PCR product was purified by the PCR
Purification kit (Qiagen), digested with DraIII and NheI, and ligated into
pGEM-AGT2 plasmid digested with the same enzymes to form pGEM-
inAGT2. From this plasmid, the 1078-bp piece fragment between DraIII and
AgeI sites was isolated and inserted into the large fragment (3 kb) from
pUC-AGT plasmid digested with the same enzymes to form pUC-inAGT2.
The resulting plasmid, pUC-inAGT2, was then used for insertion of the
random sequences. The DNA insert containing the random sequences was
created by PCR covering the AGT coding region from 420 to 540, including
the DraIII site (at 436) and the AgeI site (at 521), using as the sense primer,
59-CCGTGCCACAGAGTGGTCTGCAGCAGCGGAGCCGTGGGCAACTA-
CTCCNNSGGGCTAGCCGTGAAGG-39, and as the antisense primer, 59-
GGCTTCCCCAACCGGTGGCC-39, (mismatches underlined, and restriction
sites shown in italics). The PCR reaction was carried out using Pfu polymerase
and pUC-AGT as the template under the same conditions as described above.
The PCR product was gel-purified, digested with DraIII and AgeI enzymes,
and ligated into pUC-inAGT2 digested with the same enzymes. The ligated
products were used to transform XL1-Blue cells. An aliquot of the transfor-
mation mixture was plated on LB plates supplemented with 50 mg/ml ampi-
cillin to determine the total number of plasmid-containing bacteria, which was
found to be about 2.5 3 105. The remainder of the transformation mixture was
amplified by growing overnight. The plasmid DNA was isolated, subjected to
sequencing analysis to confirm that the randomized sequence was present, and
introduced into the TRG8 strain by electroporation. An aliquot of the sample
was plated to determine the efficiency of transformation (2 3 108 transfor-
mants/mg DNA), and the rest was amplified overnight in LB medium contain-
ing ampicillin and kanamycin (50 mg/ml each). Aliquots of this library were
either subjected to the screening process or stored at 270°C for further use.
The screening for active and BG-resistant AGT mutants was carried out as
described previously (14) using treatment with 50 mM BG for 1.5 h followed
by 40 mg/ml MNNG for 0.5 h at 25°C. Crude extracts for the determination of
AGT activity were prepared from the independent mutants grown overnight in
10 ml of LB medium by sonicating the bacterial pellet resuspended in 50 mM
Tris-HCl (pH 7.5), 0.1 mM EDTA, and 5 mM DTT for 2 min at 0°C using an
ultrasonic cell disruptor model W-225-R on pulse setting 50% duty cycle. Cell
debris was pelleted by centrifugation at 4°C for 15 min at 15,000 3 g, and the
supernatant was used to determine the AGT activity and its sensitivity to BG.
MNNG Survival Assay in the Presence of BG. TRG8 bacteria containing
plasmids expressing wild-type Y158H or Y158H/G160A AGT were grown in
5 ml of LB media containing 50 mg/ml ampicillin and 50 mg/ml kanamycin
with agitation at 250 rpm in a water bath at 37°C until the A600 was 0.5. The
cultures were then pelleted, washed, resuspended in 1 ml of LB media and
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divided into two 0.5-ml aliquots, one of which was supplemented with 250
mM BG. The tubes were agitated at 250 rpm for 1.5 h at 25°C before an
additional 2 ml of media with or without BG was added to restore the
original volume. After BG treatment, the cultures were exposed to MNNG
(0 – 40 mg/ml) for 30 min. The reactions were stopped by diluting small
aliquots of the bacteria cultures in M9 media on ice. The bacteria were
further diluted and spread on LB plates containing 50 mg/ml ampicillin and
50 mg/ml kanamycin with or without 100 mM BG. The plates were incu-
bated at 37°C for 16 h, and the colony numbers were determined. The
percentage of survival was determined by using the colony number/ml of
culture exposed to MNNG divided by the colony number/ml of culture
when MNNG was absent.
Purification of AGT. The wild type and all of the mutants except Y158F
were expressed using the pQE vector, which adds a 12-amino acid sequence
[MRGS (H)6GS-) to the NH2 terminus of the AGT protein, and were purified
by immobilized metal affinity chromatography as described previously (13,
14). The recombinant Y158F mutant protein was produced using the pIN-
Y158F plasmid and was purified as described (27).
Determination of Effects of BG on AGT Activity. Inactivation of the
AGT activity by BG in crude bacterial extracts or purified protein preparations
was measured by incubating aliquots of the protein with different concentra-
tions of BG at 37°C for 30 min in 0.5 ml of 50 mM Tris-HCl (pH 7.6), 5 mM
DTT, and 0.1 mM EDTA containing 50 mg hemocyanin and 10 mg calf thymus
DNA (14). The residual AGT activity was determined, and the results were
expressed as the percentage of the AGT activity remaining. Graphs of AGT
activity remaining against inhibitor concentration were used to calculate an
ED50 value representing the amount of inhibitor needed to produce a 50% loss
of activity.
Measurements of the formation of [8-3H]guanine from [8-3H]BG were
carried out as described previously (26) using various amounts of the purified
AGT proteins in an assay buffer consisting of 0.7 mM O6-benzyl-[3H]guanine,
25 mg of calf thymus DNA, 50 mM Tris-HCl (pH 7.6), 0.1 mM EDTA, and 5
mM DTT in an assay volume of 0.25 ml.
Kinetics of Repair by AGT. The rate constant for the AGT reaction was
determined by measuring the appearance of the [3H]methylated AGT at
various times using concentrations of AGT protein determined in preliminary
experiments to readily measurable rates under the assay conditions (29). The
reaction mixture (1 ml) for each time point contained AGT (4.5 3 10-10 M for
wild type, 2.75 3 10-9 M for Y158H, 6.5 3 10-9 M for P140K, 1.1 3 10-8 M
for P140K/Y158H or 3.4 3 10-9 M for P140K/Y158F), 3.6 3 10-10 M O6
-[3H]methylguanine in [3H]methylated DNA substrate and 50 mg of cold calf
thymus DNA in a buffer containing 50 mM Tris-HCl (pH 7.6), 5 mM DTT, and
0.5 mM EDTA.
RESULTS
A library of AGT mutants containing an NNS codon replacing
codon 160 in the human AGT was placed in the pUC18 vector and
expressed in TRG8 cells that lacked endogenous AGT activity and
were permeable to BG (14). The library was then selected by exposure
to MNNG and BG, colonies were isolated, and the AGT sequence
present was determined. One of the colonies contained a sequence
coding for the double mutation Y158H/G160A. The origin of the
second mutation producing the Y158H change is obscure but the
mutation was an A:T to G:C transition that could have been derived
from the mutagenic effects of the MNNG used for selection. The
ability of the cells carrying this mutant AGT to survive the selection
procedure suggested that the Y158H/G160A was likely to be active in
repairing methylated DNA and to be resistant to BG. This was
confirmed by direct measurement of the killing of the cells by MNNG
in the presence and absence of BG (Fig. 1) and by assays using crude
extracts from the TRG8 cells (Fig. 2).
Cells containing the Y158H/G160A mutant or wild-type AGT were
resistant to killing by MNNG. When 250 mM BG was also added, the
protection by wild-type AGT was abolished, but that by Y158H/
G160A was unaffected (Fig. 1). Direct proof that the Y158H/G160A
mutant was resistant to inactivation by BG was obtained using crude
extracts from the cells and measuring AGT activity after exposure to
the inhibitor (Fig. 2). The Y158H/G160A mutant was more than 1000
times more resistant to BG than wild type, with an ED50 value of
;180 mM as compared with ;0.1 mM.
Previous studies with the purified protein have shown that the
single mutation G160A does not render AGT resistant to BG and, in
fact, slightly increases sensitivity to this drug (13). It, therefore,
seemed likely that this mutation was not contributing to the resistance
of the Y158H/G160A double mutant, although it might aid in main-
taining the activity of the protein when the highly conserved tyrosine-
158 was replaced by histidine. To test this, the single Y158H mutant
AGT sequence was made and expressed in TRG8 cells. The cells
expressing this protein showed similar protection from MNNG to
cells expressing wild-type AGT, and this protection was not abolished
by BG (Fig. 1). Also, the Y158H-mutant AGT in crude extracts from
the TRG8 cells was actually significantly more resistant to BG inac-
tivation than the double mutant (Fig. 2).
This resistance was confirmed using AGT purified to homogeneity
Fig. 1. The effect of mutations Y158H and Y158H/G160A on the survival of MNNG-
treated TRG8 cells in the presence and absence of BG. The survival of TRG8 cells
expressing the AGT shown after treatment with the MNNG concentration indicated in the
presence of 250 mM BG (open symbols) or in the absence of BG (closed symbols) was
measured. Results are shown for cells expressing wild-type AGT (E, F), mutant Y158H
(M, f), and Y158H/G160A (, ).
Fig. 2. The sensitivity of AGT in crude cell extracts to BG. AGT inactivation studies
were carried out as described under Methods and Materials by incubation of the crude cell
extracts from TRG8 cells expressing the AGT shown with the BG concentrations indi-
cated for 30 min in the presence of 10 mg of calf thymus DNA. The residual AGT activity
was then determined by addition of a [3H]methylated DNA substrate and a further
incubation for 30 min. There was no significant loss of AGT activity on incubation in the
absence of BG.
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(Fig. 3 and Table 1). The Y158H mutant AGT was expressed using
the pQE vector, which places a (His)6-tagged sequence at the NH2
terminus. The protein was then purified using immobilized metal
affinity chromatography. As shown in Fig. 3, the ED50 for inactivation
by BG of the Y158H AGT was greatly increased, whereas the Y158F
mutation had little significant effect on the reaction with BG. The
ED50 value for Y158H was increased by more than 6000-fold over
wild-type AGT from 0.1 mM to 620 mM (Table 1).
Only one other point mutation in AGT is associated with a greater
increase in resistance to BG. This is the mutation P140K, which
renders the ED50 value more than 1200 mM (14). Models based on the
known crystal structure of the related E. coli Ada-C protein suggested
that the side chain of the lysine in the P140K mutant may be in close
proximity to the hydroxyl group of tyrosine-158 (Fig. 4). The pres-
ence of a positive charge in this location may, therefore, strongly
discourage the binding of the hydrophobic BG.
This concept was examined by the construction of the double
mutants P140K/Y158F and P140K/Y158H. These mutants and
P140K were tested for inactivation by BG, and all of them were so
highly resistant that ED50 values could not be measured, although
Y158F/P140K showed a slight reduction of activity with 1.2 mM BG
(Table 1). Measurement of the rate of guanine production when AGT
acts on BG provides a more sensitive method for determining the
interaction of AGT with BG (26). Such studies were, therefore,
carried out using [8-3H]BG as a substrate in a 20 min reaction. The
production of [8-3H]guanine by the mutants P140K, Y158H and
Y158F was consistent with the ED50 values (Table 1). As reported
previously (14), the formation of [8-3H]guanine was greatly reduced
by the P140K mutation. The Y158H mutation was slightly less effec-
tive but it also greatly reduced [8-3H]guanine formation, whereas the
Y158F mutation had only a small effect (Table 1). The P140K/Y158F
and P140K/Y158H double mutants had a highly impaired ability to
convert [8-3H]BG to [8-3H]guanine but P140K/Y158F was actually
more reactive than P140K, whereas P140K/Y158H gave no detect-
able guanine formation even when 0.6 mg of AGT protein was used
(Table 1).
Although the Y158H and P140K mutations clearly did not prevent
the ability of AGT to repair methylated DNA, they did produce a
significant effect on the rate of the reaction. As shown in Table 1,
there was an approximately 10-fold reduction in the rate constant for
DNA repair. These reductions may reflect the distortion at the active
site. The combination of the P140K mutation with the Y158H muta-
tion that may produce an even greater distortion reduced the rate
constant by a greater amount (40-fold) but the combination P140K/
Y158F gave a smaller reduction of only 4-fold. This may indicate that
the loss of the hydroxyl group from the side chain of residue 158 may
allow the lysine inserted at position 140 to be accommodated with less
of an alteration in the structure of the active site.
DISCUSSION
It is possible that the G160A alteration in the Y158H/G160A
double mutant that was selected in our screening procedure contrib-
utes to an increased activity of this mutant compensating for the
10-fold reduction in rate constant produced by the Y158H change.
However, this was not investigated in our studies because the Y158H/
G160A was not obtained in a purified form suitable for such exper-
iments. Although there was apparently a slight difference in resistance
to killing by MNNG between the cells expressing wild-type or Y158H
AGT and those expressing the Y158H/G160A double mutant with the
latter showing a greater level of protection (Fig. 1), these results
should not be taken to indicate that the double mutant is more active.
The observed difference may be an experimental artifact because the
cells expressing the double mutant were those surviving the treatment
with BG plus MNNG. These cells may have acquired additional
mutations in the bacterial genome during the selection procedure, and
they grew more slowly than the original untreated TRG8 cells in
which the wild type and the Y158H mutants were expressed. This
difference in growth rate or other effects of unknown mutations could
contribute to the difference observed.
Our results show that, although the position in all of the alkyltrans-
ferases equivalent to 158 in the human AGT is highly conserved in all
of the known AGTs and is restricted to tyrosine or occasionally
phenylalanine, the substitution with histidine also gives rise to an
active protein. It is possible that these amino acids are the only ones
tolerated at this position because mutant Y158A was inactive (27),
and no AGTs with other alterations at position 158 have been found
in screens of mutated AGT libraries. The ability of histidine to replace
tyrosine-158 and to provide an active AGT is also suggested by recent
results of the screening using BG and MNNG for the selection of
plasmid libraries in which random mutagenesis was used for substi-
tutions of positions 150–172 of AGT (16). All of the BG-resistant
mutants found had multiple substitutions with 3–5 amino acids dif-
fering from wild type, but 5 of 8 of these mutants had the Y158H
Fig. 3. The effect of BG on purified AGT proteins. Inactivation studies were carried out
as described in the legend to Fig. 2 using purified AGT proteins. Results for Y158H and
wild type AGT are shown in the main figure. The insert shows results with wild-type and
Y158F-mutant AGT proteins.
Table 1 Properties of AGT mutant proteins
Mutant
Inactivation by BG
(ED50, mM)
Conversion of
[8-3H]BG to
[8-3H]guanine (cpm/mg protein)
Rate constant for reaction with
methylated DNA
(M21zmin21)
Wild type 0.1 13,879 38 3 106
Y158F 0.2 7,653 Not measured
Y158H 620 30.1 3.4 3 106
Y158A Inactive Inactive Inactive
P140K .1200 (99% remaining at 1.2 mM) 2.0 3.6 3 106
P140K/Y158H .1200 (99% remaining at 1.2 mM) ,0.1 1.0 3 106
P140K/Y158F .1200 (88% remaining at 1.2 mM) 7.0 9.4 3 106
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change. Our results suggest that this alteration was the major reason
for the resistance of these mutants to BG.
Several microbial AGTs including the Ada-C protein from E. coli
are virtually unaffected by BG (9). Studies by site-directed mutagen-
esis and comparison with the known crystal structure for this protein
(30, 31) have indicated that the resistance of the E. coli Ada-C AGT
is due to a steric restriction of the size at the active site that prevents
the binding of the bulky BG (32, 33). This restriction is caused by the
combination of the absence of a proline and the presence of a tryp-
tophan residue in the active site pocket. The mutation of both of these
residues to form proline and alanine, respectively, renders Ada-C able
to react with BG (32, 33).
The inability of the first reported BG-resistant mutants of the
human AGT (P140A and G156A) to react well with this drug also
seems to be due to steric factors inasmuch as these alterations would
be expected to reduce the size of the active site pocket in the human
AGT (11, 12). However, the discovery that the G160R mutant was
also resistant, whereas G160A and G160W were not (and were
actually more sensitive), suggested that another class of resistant
mutants might be formed by the presence of a hydrophilic group in the
active site pocket (13).
The finding that the Y158H-mutant AGT is highly resistant to
inactivation by BG (ED50 of 620 mM) provides strong support for this
hypothesis. Its resistance can be explained by the presence of a
charged residue in the active-site pocket that discourages the binding
of the hydrophobic BG. The other two single amino acid changes that
have the largest effect in rendering AGT resistant to BG are P140K
(ED50 of . 1200 mM) and P140R (ED50 of 190 mM; Ref. 14). These
changes are also likely to lead to placing a charged residue in the
active site and may also influence the reaction by the steric effect
caused by replacing the proline described above.
The combination of the P140K and Y158H mutations forming
mutant P140K/Y158H rendered human AGT totally unable to react
with BG. The limit of detection in the assays shown in Table 1 is such
that the reduction in rate of reaction of this double mutant when
compared with wild type is by a factor of more than 105. This
P140K/Y158H mutant was considerably less active with BG than the
single P140K mutant. Although a small part of this reduction may be
due to the difference in rate constant between these two mutants, this
was altered by only a factor of 3.6, whereas the reduction in the rate
of guanine formation from BG was more than 20-fold (Table 1). In
contrast, the increased ability of the P140K/Y158F to react with BG
when compared with P140K alone may be due solely to the alteration
in the rate constant.
Although both the P140K- and the Y158H-mutated AGT proteins
have a significant reduction in the rate constant for the repair of
methylated DNA, this does not prevent them from being highly
effective in protecting E. coli from killing by MNNG (Fig. 1 and
reference (14)) or, in the case of P140K, from protecting mammalian
cells from the therapeutic agent BCNU (34). This is probably due to
the very rapid rate of repair by the wild-type AGT. A moderate
reduction in this rate, therefore, has little physiological effect. In
studies with other mutants of AGT in the DNA binding domain that
are more severely compromised in their activity, a greater than 35-fold
reduction was required before any effect was observed. Even mutant
Y114A, which had almost a 1000-fold reduction in rate constant,
provided some protection (29).
The protection from killing by alkylating agents afforded by mu-
tants Y158H and P140K was not reduced by BG even at concentra-
tions far in excess of those likely to be achievable in patients treated
with this drug. Therefore, these mutants are excellent choices for gene
therapy approaches in which the expression of a BG-resistant mutant
Fig. 4. Model of partial structure of P140K and
Y158H mutant AGTs. The figures were generated
using the program Ras-Mol using the coordinates
for the model of human AGT (36) and inserting the
point mutations with the Swiss protein data base
viewer program. The spatial arrangement of the
protein chain at the active site is shown with the
side chains of residues 140, 145, and 158 shown as
ball and stick structures.
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AGT in hematopoietic progenitor cells is used to protect the bone
marrow and improve the therapeutic index of such therapy.
Conversely, the relatively facile production of BG-resistant mutants
that is revealed in these and other experiments suggests that the
formation or selection for such forms of AGT in tumor cells during
therapy may be a significant problem although these forms have
lower-than-wild-type-AGT activity. This focuses attention on the
development of novel inhibitors that could be used to inactivate such
forms. The use of short single-stranded oligodeoxynucleotides con-
taining an O6-benzyldeoxyguanosine may be useful in this regard
because the binding of these to the AGT-active site involves the DNA
binding domain and is much stronger than the binding of the free base
BG (35).
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